StockData
Cooper Companies, Inc. logo

Cooper Companies, Inc.

COONasdaqOphthalmic GoodsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.75+0.03 (+0.05%)

Close on Nov 18, 2026Market cap $11.55BP/E 20.7Yield –

Cooper Companies ClinicalTrials.gov by Quarter

ClinicalTrials.gov — Sponsored Studies Started (CooperVision & CooperSurgical)

Periods

Cooper Companies ClinicalTrials.gov: 1 in Q4 FY26, unchanged from a year earlier. That is the lowest of the 39 quarters on record here.

Latest, Q4 FY26
1
Period ended Oct 31, 2026 (CQ3 2026)
Change on a year earlier
0.0%
1 in Q4 FY25
History
39 quarters
Since Q1 FY17
Sources
1
U.S. National Library of Medicine — ClinicalTrials.gov Registry

Where the Q4 FY26 figure comes from

Source: U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedClinicalTrials.gov — Sponsored Studies Started (CooperVision & CooperSurgical)Year on yearSource
Q4 FY26CQ3 2026Oct 31, 202610.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q3 FY26CQ2 2026Jul 31, 20263+200.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q2 FY26CQ1 2026Apr 30, 20261-50.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q1 FY26CQ4 2025Jan 31, 20262-50.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q4 FY25CQ3 2025Oct 31, 20251-66.7%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q3 FY25CQ2 2025Jul 31, 20251-66.7%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q2 FY25CQ1 2025Apr 30, 20252-50.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q1 FY25CQ4 2024Jan 31, 20254-33.3%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q4 FY24CQ3 2024Oct 31, 20243+50.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q3 FY24CQ2 2024Jul 31, 20243–U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q2 FY24CQ1 2024Apr 30, 20244+33.3%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q1 FY24CQ4 2023Jan 31, 20246+100.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q4 FY23CQ3 2023Oct 31, 20232-75.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q2 FY23CQ1 2023Apr 30, 202330.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q1 FY23CQ4 2022Jan 31, 20233-25.0%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
Q4 FY22CQ3 2022Oct 31, 20228+166.7%U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗

Breakdown

What makes up clinicalTrials.gov

Cite this data

StockData. (2026). Cooper Companies ClinicalTrials.gov, quarterly Q1 FY17–Q4 FY26 [Data set]. Compiled from Cooper Companies SEC filings and investor materials. https://stockdatahq.com/stocks/coo/kpis/ct-studies-started

See every metric in the Cooper Companies KPI table. Data updated Nov 18, 2026.

See a number that looks wrong?